Related Experiment Videos
Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients
1Department of Psychiatry & Neuropsychology, State University of Limburg, Maastricht, The Netherlands.
Biological Psychiatry
|November 1, 1996
Abstract:
A group of 20 patients who met the DSM-III-R criteria for panic disorder with or without agoraphobia underwent a 35% carbon dioxide (CO2) challenge after either 1 mg alprazolam or placebo in a double-blind, randomized, cross-over design. Despite the anxiolytic potential of alprazolam, it produced no significant effects on CO2-induced anxiety and panic symptomatology when compared to placebo.